Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).

Shares in several pharmaceutical and biotechnology companies have fallen since President-elect Trump announced Thursday that ...

It's not just vaccine makers that are down following the announcement that former President Donald Trump has nominated Robert ...

Wolfe Research argues that despite a near-term impact, large-cap U.S. pharma stocks are largely immune from the anti-chronic ...